Abstract
A patient classified as HCV-1a-positive by both LiPA Siemens 2.0 and Abbott RealTime HCV Genotype II was instead found to be infected with HCV-1g, as determined by phylogenetic analysis of NS3 sequences. HCV-1g NS3 sequences available to date naturally harbour the resistance substitution T54S, plus P131S and L135F changes, located in the highly conserved NS3 positions within the boceprevir-binding site, as determined by structural modelling. HCV-1g NS3 sequences show some similarities to HCV-4 and are poorly responsive to interferon/ribavirin and to boceprevir/telaprevir; this patient was also a null-responder to boceprevir treatment. Baseline genotypic resistance testing may provide crucial information for the management of first-generation protease-inhibitor-based regimens, including both HCV genotype/subtype and natural resistance.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Amino Acid Sequence
-
Amino Acid Substitution
-
Antiviral Agents / therapeutic use*
-
Drug Resistance, Viral / drug effects
-
Drug Resistance, Viral / genetics*
-
Genotyping Techniques
-
Hepacivirus / drug effects
-
Hepacivirus / genetics*
-
Hepatitis C, Chronic / drug therapy*
-
Hepatitis C, Chronic / virology
-
Humans
-
Male
-
Models, Molecular
-
Molecular Sequence Data
-
Phylogeny
-
Proline / analogs & derivatives*
-
Proline / therapeutic use
-
Protease Inhibitors / therapeutic use*
-
Treatment Failure
-
Viral Nonstructural Proteins / classification
-
Viral Nonstructural Proteins / genetics*
Substances
-
Antiviral Agents
-
NS3 protein, hepatitis C virus
-
Protease Inhibitors
-
Viral Nonstructural Proteins
-
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
-
Proline